LRRK2 Gene

Aliases
for LRRK2 gene

Previous GC identifers: GC00U914055 GC12P038908 GC12P037646

Summaries
for LRRK2 gene

Genomic Views
for LRRK2 gene

RefSeq DNA sequence:

NC_000012.11  NC_018923.1  NT_029419.12  

SwitchGear Promoter luciferase reporter plasmid: LRRK2 promoter sequence

QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays in human, mouse, rat LRRK2

LRRK2 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)


GeneLoc information about chromosome 12         GeneLoc Exon Structure

GeneLoc location for GC12P040590:  view genomic region     (about GC identifiers)

Proteins
for LRRK2 gene

2 PDB 3D structures from and Proteopedia for LRRK2:

2ZEJ (3D)        3D6T (3D)    

Explore the universe of human proteins at neXtProt for LRRK2: NX_Q5S007

Post-translational modifications:

	EMD Millipore Purified and/or Recombinant LRRK2 Protein
	Browse R&D Systems for human recombinant proteins
	Browse recombinant and purified proteins available from Enzo Life Sciences
	Browse OriGene full length recombinant human proteins expressed in human HEK293 cells Browse OriGene Protein Over-expression Lysates OriGene Custom Protein Services for LRRK2
	GenScript Custom Purified and Recombinant Proteins Services for LRRK2
	Novus Biologicals LRRK2 Proteins
	Browse Sino Biological Recombinant Proteins
	Browse ProSpec Recombinant Proteins
	Uscn Proteins for LRRK2

Gene Ontology (GO): 5/11 cellular component terms (GO ID links to tree view) (see all 11):    About this table

	EMD Millipore Mono- and Polyclonal Antibodies for the study of LRRK2
	R&D Systems Antibodies for LRRK2
	Cell Signaling Technology (CST) Antibodies for LRRK2
	OriGene Antibodies (see all 3): LRRK2 OriGene Custom Antibody Services for LRRK2
	GenScript Custom Superior Antibodies Services for LRRK2
	Novus Biologicals LRRK2 Antibodies
	Abcam antibodies for LRRK2
	Uscn Antibodies for LRRK2
	ThermoFisher Antibody for LRRK2

	Browse Kits and Assays available from EMD Millipore
	OriGene Custom Immunoassay Development Browse OriGene Fluorogenic Cell Assay Kits
	Browse R&D Systems for biochemical assays
	GenScript Custom Assay Services for LRRK2
	Browse Enzo Life Sciences for kits & assays
	Uscn ELISAs and CLIAs for LRRK2

Protein Domains /
Families
for LRRK2 gene

ProtoNet protein and cluster: Q5S007

Function
for LRRK2 gene

Enzyme Number (IUBMB): EC 2.7.11.1¹

miRNA Products:		OriGene 3'-UTR Clone: LRRK2 Browse MicroRNA Expression Plasmids
		QIAGEN Custom miScript Target Protector blocks miRNA-binding site of human, mouse, rat LRRK2
		8/17 QIAGEN miScript miRNA Assays for microRNAs that regulate LRRK2 (see all 17):
		hsa-miR-607 hsa-miR-181c hsa-miR-301a hsa-miR-130b hsa-miR-181b hsa-miR-301b hsa-miR-205 hsa-miR-181a
		SwitchGear 3'UTR luciferase reporter plasmid: LRRK2 3' UTR sequence

Inhib. RNA Products:		Browse for Gene Knock-down Tools from EMD Millipore
		OriGene 29mer shRNA kits in GFP-retroviral vector in human, mouse, rat for LRRK2 (see all 4) OriGene shRNA RFP: LRRK2 OriGene siRNA: LRRK2
		QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat LRRK2

Gene Editing Products:

DNA2.0 Custom Protein Engineering Service for LRRK2

Clone Products:		Browse Clones for the Expression of Recombinant Proteins Available from EMD Millipore
		OriGene Myc/DDK tagged cDNA clones in CMV expression vector in human, mouse, rat for LRRK2 (see all 2) OriGene untagged cDNA clones in CMV expression vector in human, mouse, rat for LRRK2 OriGene custom cloning services – gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
		GenScript: all cDNA clones in your preferred vector: LRRK2 (NM_198578)
		Browse Sino Biological Human cDNA Clones
		DNA2.0 Custom Codon Optimized Gene Synthesis Service for LRRK2
		Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat LRRK2

Cell Line Products:		GenScript Custom overexpressing Cell Line Services for LRRK2
		Search LifeMap BioReagents cell lines for LRRK2

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for LRRK2

Gene Ontology (GO): 5/14 molecular function terms (GO ID links to tree view) (see all 14):    About this table

(inferred from 12 alleles) (MGI details for Lrrk2)

Pathways & Interactions
for LRRK2 gene

	Super-pathway	contained gene-specific pathways
1	Neuroscience	Neuroscience 1.00
2	MAPK signaling pathway	MAPK signaling pathway 1.00
3	Parkinsons Disease Pathway	Parkinsons Disease Pathway 1.00
4	Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.	Parkinson's disease 0.61
5	Wnt Signaling Pathway	Wnt Signaling Pathway and Pluripotency 0.55

1 Cell Signaling Technology (CST) Pathway for LRRK2

Neuroscience

3 BioSystems Pathways for LRRK2

	MAPK signaling pathway
	Wnt Signaling Pathway and Pluripotency
	Parkinsons Disease Pathway

1         Kegg Pathway  (Kegg details for LRRK2)

Parkinson's disease

Gene Ontology (GO): 5/33 biological process terms (GO ID links to tree view) (see all 33):    About this table

Drugs & Compounds
for LRRK2 gene

Transcripts
for LRRK2 gene

Expression
for LRRK2 gene

LRRK2 expression in normal human tissues (normalized intensities)
See probesets specificity/sensitivity at GeneAnnot
About this imageBioGPS
CGAP TAG: --

Stem Cell Differentiation: 1 LifeMap Cell
	Name			Category
	Human kidney epithelial cell spheroids (Kidney spheroids for...)
Expression: Positive    Negative     Selective marker Experimental details: Curated     Microarrays     In-situ hybridization

Primer Products:		OriGene genome-wide validated SYBR primer pairs in human, mouse, rat for LRRK2 Browse OriGene validated miRNA SYBR primer pairs
		SABiosciences RT2 qPCR Primer Assay in human, mouse, rat LRRK2
		QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat LRRK2
		QIAGEN QuantiFast Probe-based Assays in human, mouse, rat LRRK2

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for LRRK2

Orthologs
for LRRK2 gene

Paralogs
for LRRK2 gene

Paralogs for LRRK2 gene

LRRK1²  

3 SIMAP similar genes for LRRK2 using alignment to 5 protein entries:     LRRK2_HUMAN (see all proteins):

DKFZp686E15222    AURA17    STK11

LRRK2 for paralogs           About GeneDecksing

Genomic Variants
for LRRK2 gene

10/3532 NCBI SNPs in LRRK2 are shown (see all 3532)     About this table

Genomic Data					Transcription Related Data				Allele Frequencies
SNP ID	Valid	Clinical significance	Chr 12 pos	Sequence	#	AA Chg	Type	More	#	Allele freq	Pop	Total sample	More
-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	--	--	--	-1st2nd3rd	--	--	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd
rs345944981,2	C,F,	pathogenic	37674515(+)	ATCTGC/TGAATG	2	A V	mis1		4		EA NA	5242
rs344109871,2	C,F,	pathogenic	37705347(+)	CAGTCC/TCAAAT	2	P L	mis1		3		EA NA	188
rs358083891,2	C	pathogenic	37719923(+)	ATTTTA/GGAAGG	2	L	syn1		2		NA	4550
rs348056041,2	C	pathogenic	37720560(+)	CAGGGA/GTATGC	2	I V	mis1		2		NA	4
rs741636861,2	C	pathogenic	37730660(+)	TCTTCA/CATATA	2	N H	mis1		0	--	--	--	--
rs339399271,2	C	pathogenic	37731869(+)	AGGCTC/G/TGCGCT	3	R G C	mis1		2		NA	4
rs349953761,2	C	pathogenic	37731870(+)	GGCTCG/ACGCTT	2	/H /R	mis1		2		NA	4
rs339493901,2	C,F,	pathogenic	37741479(+)	TTCGCA/C/GTAGAG	3	H P R	mis1		3		NA	4156
rs358014181,2	C	pathogenic	37742550(+)	GCCTTA/GTTTTC	2	Y C	mis1		1		NA	2
rs346375841,2	C,F,	pathogenic	37761838(+)	ACTACG/AGCATT	2	/S /G	mis1		4		NA EU	5875

HapMap Linkage Disequilibrium report for LRRK2 (40590546 - 40763087 bp)
Structural Variations (Copy Number Variations, Insertions/Deletions, Inversions)
Database of Genomic Variants (DGV): 3 variations for LRRK2
     2 CNVs: 101488 101487
     1 Indel: 58569
Human Gene Mutation Database (HGMD): LRRK2

Locus Specific Mutation Databases (LSDB): LRRK2

SABiosciences Cancer Mutation PCR Assays

QIAGEN SeqTarget long-range PCR primers in human, mouse, rat for resequencing LRRK2

DNA2.0 Custom Variant and Variant Library Synthesis for LRRK2

Disorders / Diseases
for LRRK2 gene

20/31 diseases for LRRK2

10/18 Novoseek disease relationships for LRRK2 gene (see all 18)    About this table

Publications
for LRRK2 gene

PubMed articles for LRRK2 gene, integrated from 9 sources (see all 562) (see top 10): (articles sorted by number of sources associating them with LRRK2)

Utopia: connect your pdf to the dynamic world of online information

1. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. (PubMed id 16157901)^{1, 2, 4, 9} Paisan-Ruiz C....Rogaeva E. (2005)
2. LRRK2 mutations are not common in Alzheimer's disease. (PubMed id 16087219)^{1, 2, 4, 9} Toft M....Farrer M.J. (2005)
3. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. (PubMed id 16157909)^{1, 2, 4, 9} Zabetian C.P.... Griffith A. (2005)
4. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. (PubMed id 16250030)^{1, 2, 4, 9} Kay D.M.... Payami H. (2006)
5. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. (PubMed id 16272257)^{1, 2, 4, 9} Goldwurm S.... Bonifati V. (2005)
6. Clinical features of LRRK2-associated Parkinson's disease in central Norway. (PubMed id 15852371)^{1, 2, 4, 9} Aasly J.O.... Farrer M.J. (2005)
7. A common LRRK2 mutation in idiopathic Parkinson's disease. (PubMed id 15680457)^{1, 2, 4, 9} Gilks W.P.... Wood N.W. (2005)
8. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. (PubMed id 16298482)^{1, 2, 4} Infante J.... Berciano J. (2006)
9. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. (PubMed id 16240353)^{1, 2, 4} Lesage S....Brice A. (2005)
10. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. (PubMed id 16251215)^{1, 2, 4} Berg D.... Naegele T. (2005)
11. LRRK2 R1441G in Spanish patients with Parkinson's disease. (PubMed id 15925109)^{1, 2, 4} Mata I.F.... Alvarez V. (2005)
12. LRRK2 mutations in Parkinson disease. (PubMed id 16157908)^{1, 2, 4} Farrer M.... Maraganore D.M. (2005)
13. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. (PubMed id 15541308)^{1, 2, 3} Paisan-Ruiz C....Singleton A.B. (2004)
14. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal degeneration. (PubMed id 16352719)^{1, 2, 9} Smith W.W.... Ross C.A. (2005)
15. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. (PubMed id 16272164)^{1, 2, 9} Khan N.L....Wood N.W. (2005)
16. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. (PubMed id 16269541)^{1, 2, 9} West A.B.... Dawson T.M. (2005)
17. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. (PubMed id 16321986)^{1, 2, 9} Gloeckner C.J.... Ueffing M. (2006)
18. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. (PubMed id 16533964)^{1, 2, 9} Gaig C....Tolosa E. (2006)
19. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. (PubMed id 18213618)^{1, 2, 9} Paisan-Ruiz C.... Singleton A.B. (2008)
20. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. (PubMed id 16081470)^{1, 2, 9} Adams J.R.... Stoessl A.J. (2005)
21. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. (PubMed id 15726496)^{1, 2, 9} Kachergus J.M.... Toft M. (2005)
22. Mutations in a large multifunctional protein (LRRK2) cause autosomal dominant parkinsonism with pleiomorphic a-synuclein and tau-pathology (PARK8). (PubMed id 15541309)^{1, 2, 9} Zimprich A.... Gasser T. (2004)
23. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. (PubMed id 16254973)^{1, 4, 9} Biskup S....Gasser T. (2005)
24. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. (PubMed id 15680456)^{1, 2, 9} Di Fonzo A....Bonifati V. (2005)
25. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. (PubMed id 15732108)^{1, 2, 9} Hernandez D.G.... Singleton A.B. (2005)
26. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. (PubMed id 16102903)^{1, 4, 9} Hernandez D....Singleton A. (2005)
27. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. (PubMed id 15680455)^{1, 2, 9} Nichols W.C.... Foroud T. (2005)
28. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. (PubMed id 15880653)^{1, 2, 9} Funayama M.... Obata F. (2005)
29. Lrrk2 pathogenic substitutions in Parkinson's disease. (PubMed id 16172858)^{1, 2, 9} Mata I.F.... Farrer M.J. (2005)
30. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. (PubMed id 16115731)^{1, 4, 9} Bialecka M....Drozdzik M. (2005)
31. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. (PubMed id 22952686)^{1, 2} Civiero L.... Taymans J.M. (2012)
32. Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. (PubMed id 22415848)^{1, 2} Rubio J.P.... Mooser V.E. (2012)
33. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. (PubMed id 21850687)^{1, 2} Angeles D.C.... Tan E.K. (2011)
34. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. (PubMed id 21641266)^{1, 2} Bardien S....Carr J. (2011)
35. Signal transduction protein array analysis links LRRK 2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. (PubMed id 20949042)^{1, 2} Zach S....Gillardon F. (2010)
36. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. (PubMed id 17019612)^{1, 2} Tan E.K.... Liu J.J. (2007)
37. LRRK2 expression linked to dopamine-innervated areas. (PubMed id 16532471)^{1, 2} Galter D....Olson L. (2006)
38. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. (PubMed id 16333314)^{1, 2} Di Fonzo A....Bonifati V. (2006)
39. Analysis of LRRK2 functional domains in nondominant Parkinson disease. (PubMed id 16247070)^{1, 2} Skipper L.... Tan E.K. (2005)
40. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. (PubMed id 16001413)^{1, 2} Kay D.M.... Payami H. (2005)
41. Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. (PubMed id 16102999)^{1, 2} Gosal D.... Mark Gibson J. (2005)
42. LRRK2 mutations and Parkinsonism. (PubMed id 15811454)^{1, 2} Toft M.... Farrer M.J. (2005)
43. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. (PubMed id 15929036)^{1, 2} Deng H.... Jankovic J. (2005)
44. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. (PubMed id 15955629)^{1, 4} Tan E.K....Liu J.J. (2005)
45. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. (PubMed id 16269443)^{1, 4} Skipper L....Liu J. (2005)
46. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. (PubMed id 18045479)^{1, 9} Biskup S....West A.B. (2007)
47. GTPase activity plays a key role in the pathobiology of LRRK2. (PubMed id 20386743)^{1, 9} Xiong Y....Moore D.J. (2010)
48. Dependence of leucine-rich repeat kinase 2 (LRRK2) ki nase activity on dimerization. (PubMed id 19826009)^{1, 9} Sen S....West A.B. (2009)
49. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. (PubMed id 17971075)^{1, 9} Alegre-Abarrategui J....Wade-Martins R. (2008)
50. The Parkinson's disease associated LRRK2 exhibits wea ker in vitro phosphorylation of 4E-BP compared to autophosphorylation. (PubMed id 20090955)^{1, 9} Kumar A....Cookson M.R. (2010)
51. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. (PubMed id 18435766)^{1, 9} Pchelina S.N....Singleton A.B. (2008)
52. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. (PubMed id 17512502)^{1, 9} Higashi S....Emson P.C. (2007)
53. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. (PubMed id 17611037)^{1, 9} Melrose H.L....Farrer M.J. (2007)
54. Sequence conservation between porcine and human LRRK2. (PubMed id 17978862)^{1, 9} Larsen K. and Madsen L.B. (2009)
55. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. (PubMed id 18322396)^{1, 9} Perry G....Chen S.G. (2008)
56. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. (PubMed id 17804834)^{1, 9} Nichols W.C....Foroud T. (2007)
57. LRRK2 modulates vulnerability to mitochondrial dysfun ction in Caenorhabditis elegans. (PubMed id 19625511)^{1, 9} Saha S....Wolozin B. (2009)
58. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. (PubMed id 18272292)^{1, 9} Westerlund M....Galter D. (2008)
59. Identification of the autophosphorylation sites of LR RK2. (PubMed id 19824698)^{1, 9} Kamikawaji S....Iwatsubo T. (2009)
60. Leucine-rich repeat kinase 2 associates with lipid rafts. (PubMed id 17341485)^{1, 9} Hatano T....Hattori N. (2007)
61. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. (PubMed id 17706965)^{1, 9} Guo L....Chen S.G. (2007)
62. The Parkinson disease gene LRRK2: evolutionary and structural insights. (PubMed id 16966681)^{1, 9} Marin I. (2006)
63. MKK6 binds and regulates expression of Parkinson's di sease-related protein LRRK2. (PubMed id 20067578)^{1, 9} Hsu C.H....Wolozin B. (2010)
64. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. (PubMed id 19025767)^{1, 9} Gandhi P.N....Wilson-Delfosse A.L. (2009)
65. LRRK2 p.G2019S mutation is not common among Alzheimer 's disease patients in Brazil. (PubMed id 19822953)^{1, 9} Santos-RebouAsas C.B....Pimentel M.M. (2009)
66. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. (PubMed id 18367605)^{1, 9} Wang L....Cai H. (2008)
67. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. (PubMed id 18338801)^{1, 9} Lu Y.W. and Tan E.K. (2008)
68. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. (PubMed id 18936941)^{1, 9} Huang Y....Halliday G.M. (2008)
69. Leucine-rich repeat kinase 2 phosphorylates brain tub ulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? (PubMed id 19545277)^{1, 9} Gillardon F. (2009)
70. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. (PubMed id 19680143)^{1, 9} Higashi S....Iseki E. (2009)
71. The WD40 domain is required for LRRK2 neurotoxicity. (PubMed id 20041156)^{1, 9} Jorgensen N.D....Dauer W.T. (2009)
72. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. (PubMed id 19076219)^{1, 9} Anand V.S....Braithwaite S.P. (2009)
73. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. (PubMed id 18701920)^{1, 9} Imai Y....Lu B. (2008)
74. The biology and pathobiology of LRRK2: implications for Parkinson's disease. (PubMed id 18602856)^{1, 9} Moore D.J. (2008)
75. Mutations in LRRK2 as a cause of Parkinson's disease. (PubMed id 18097165)^{1, 9} Giasson B.I. and Van Deerlin V.M. (2008)
76. LRRK2 regulates synaptic vesicle endocytosis. (PubMed id 18445495)^{1, 9} Shin N....Seol W. (2008)
77. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. (PubMed id 18675914)^{1, 9} Liou A.K....Zigmond M.J. (2008)
78. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. (PubMed id 17260967)^{1, 9} Ito G....Iwatsubo T. (2007)
79. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. (PubMed id 17222106)^{1, 9} Xiromerisiou G....Singleton A.B. (2007)
80. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. (PubMed id 17353388)^{1, 9} Lesage S....Verin M. (2007)
81. Mutations in the Parkinson's disease genes, Leucine R ich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated wi th essential tremor. (PubMed id 19527940)^{1, 9} Clark L.N....Louis E.D. (2010)
82. LRRK2 in Parkinson's disease: genetic and clinical st udies from patients. (PubMed id 19804413)^{1, 9} Kumari U. and Tan E.K. (2009)
83. Parkin protects against LRRK2 G2019S mutant-induced d opaminergic neurodegeneration in Drosophila. (PubMed id 19741132)^{1, 9} Ng C.H....Lim K.L. (2009)
84. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. (PubMed id 18214993)^{1, 9} Gandhi P.N....Wilson-Delfosse A.L. (2008)
85. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. (PubMed id 16758483)^{1, 9} Hedrich K....Klein C. (2006)
86. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. (PubMed id 16750377)^{1, 9} Greggio E....Cookson M.R. (2006)
87. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. (PubMed id 17095157)^{1, 9} Dachsel J.C....Farrer M.J. (2006)
88. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. (PubMed id 20074637)^{1, 9} Carballo-Carbajal I....Kahle P.J. (2010)
89. A comparative study of LRRK2, PINK1 and genetically u ndefined familial Parkinson's disease. (PubMed id 19726410)^{1, 9} Nishioka K....Hentati F. (2010)
90. Prevalence and clinical features of LRRK2 mutations i n patients with Parkinson's disease in southern Spain. (PubMed id 19473361)^{1, 9} Gao L....Mir P. (2009)
91. LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. (PubMed id 19343804)^{1, 9} Zabetian C.P....Kawakami H. (2009)
92. Homo- and heterodimerization of ROCO kinases: LRRK2 k inase inhibition by the LRRK2 ROCO fragment. (PubMed id 19712061)^{1, 9} Klein C.L....Kahle P.J. (2009)
93. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. (PubMed id 18980856)^{1, 9} Mata I.F....Zabetian C.P. (2008)
94. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. (PubMed id 17914064)^{1, 9} Chen-Plotkin A.S....Van Deerlin V.M. (2008)
95. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. (PubMed id 18097693)^{1, 9} Habig K....Bonin M. (2008)
96. LRRK2 is not a significant cause of Parkinson's disease in French-Canadians. (PubMed id 17803032)^{1, 9} Dupre N....Rouleau G.A. (2007)
97. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. (PubMed id 17200152)^{1, 9} West A.B....Dawson T.M. (2007)
98. LRRK2 and Parkinson's disease in Norway. (PubMed id 17419834)^{1, 9} Toft M....Aasly J.O. (2007)
99. LRRK2 screening in a Canadian Parkinson's disease cohort. (PubMed id 17803033)^{1, 9} Grimes D.A....Bulman D.E. (2007)
100. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. (PubMed id 17427941)^{1, 9} Huang Y....Sue C.M. (2007)
101. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. (PubMed id 17394548)^{1, 9} Greggio E....Cookson M.R. (2007)
102. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. (PubMed id 17097110)^{1, 9} Deng H....Jankovic J. (2006)
103. LRRK2 in Parkinson's disease: protein domains and functional insights. (PubMed id 16616379)^{1, 9} Mata I.F....Gallo K.A. (2006)
104. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. (PubMed id 19769964)^{1, 9} Heo H.Y....Seol W. (2010)
105. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. (PubMed id 20197701)^{1, 9} Wider C....Wszolek Z.K. (2010)
106. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. (PubMed id 19176810)^{1, 9} Ho C.C....Dauer W.T. (2009)
107. Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. (PubMed id 19205068)^{1, 9} Camargos S.T....Cardoso F. (2009)
108. Genetic factors influencing age at onset in LRRK2-lin ked Parkinson disease. (PubMed id 19041274)^{1, 9} Golub Y....Fuchs J. (2009)
109. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. (PubMed id 19302196)^{1, 9} Gloeckner C.J....Ueffing M. (2009)
110. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. (PubMed id 18434642)^{1, 9} Gan-Or Z....Orr-Urtreger A. (2008)
111. LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease. (PubMed id 18752982)^{1, 9} Patra B....Parsian A. (2008)
112. Is the G2019S LRRK2 mutation common in all southern European populations? (PubMed id 18617409)^{1, 9} Papapetropoulos S....Chroni E. (2008)
113. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. (PubMed id 17388990)^{1, 9} Illarioshkin S.N....Ivanova-Smolenskaya I.A. (2007)
114. Identification of potential protein interactors of Lrrk2. (PubMed id 17400507)^{1, 9} Dachsel J.C....Farrer M.J. (2007)
115. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. (PubMed id 17440812)^{1, 9} Bonifati V. (2007)
116. Apoptotic mechanisms in mutant LRRK2-mediated cell death. (PubMed id 17409193)^{1, 9} Iaccarino C....Barone P. (2007)
117. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. (PubMed id 17584768)^{1, 9} Luzon-Toro B....Hilfiker S. (2007)
118. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. (PubMed id 17080443)^{1, 9} Schupbach M....Brice A. (2007)
119. Kinase activity of mutant LRRK2 mediates neuronal toxicity. (PubMed id 16980962)^{1, 9} Smith W.W....Ross C.A. (2006)
120. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. (PubMed id 16817197)^{1, 9} Carmine Belin A....Galter D. (2006)
121. Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. (PubMed id 16467219)^{1, 9} Paisan-Ruiz C....Singleton A.B. (2006)
122. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. (PubMed id 18704525)^{1, 9} Choi J.M....Kim Y.J. (2008)
123. Leucine-rich repeat kinase 2 mutations and Parkinson' s disease: three questions. (PubMed id 19570025)^{1, 9} Greggio E. and Cookson M.R. (2009)
124. Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy. (PubMed id 18621566)^{1, 9} De Rosa A....De Michele G. (2008)
125. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. (PubMed id 17433753)^{1, 9} Warren L....Hentati F. (2008)
126. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: Importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. (PubMed id 18805725)^{1, 9} Floris G....Marrosu M.G. (2008)
127. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. (PubMed id 18197194)^{1, 9} Nuytemans K....van Broeckhoven C. (2008)
128. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. (PubMed id 18973254)^{1, 9} Macedo M.G....Heutink P. (2008)
129. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. (PubMed id 19021752)^{1, 9} Devine M.J. and Lewis P.A. (2008)
130. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. (PubMed id 18523869)^{1, 9} Lin C.H....Wu R.M. (2008)
131. A study of LRRK2 mutations and Parkinson's disease in Brazil. (PubMed id 18201824)^{1, 9} Pimentel M.M....Santos-Reboucas C.B. (2008)
132. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. (PubMed id 17614198)^{1, 9} Perez-Pastene C....Segura-Aguilar J. (2007)
133. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. (PubMed id 17469194)^{1, 9} Ferreira J.J....Bonifati V. (2007)
134. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. (PubMed id 17523199)^{1, 9} Haubenberger D....Zimprich A. (2007)
135. [A PARK8 form of Parkinson's disease: a mutational analysis of the LRRK2 gene in Russian population.] (PubMed id 18379513)^{1, 9} Shadrina M.I....Ivanova-Smolenskaia I.A. (2007)
136. Clinical heterogeneity of the LRRK2 G2019S mutation. (PubMed id 16966501)^{1, 9} Papapetropoulos S....Mash D.C. (2006)
137. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease. (PubMed id 17253937)^{1, 9} Funalot B....Lucotte G. (2006)
138. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. (PubMed id 17052850)^{1, 9} Punia S....Thelma B.K. (2006)
139. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. (PubMed id 16966502)^{1, 9} Ishihara L....Hentati F. (2006)
140. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. (PubMed id 16991141)^{1, 9} Simon-Sanchez J....Perez-Tur J. (2006)
141. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. (PubMed id 17050822)^{1, 9} Clark L.N....Marder K. (2006)
142. LRRK2 and Parkin mutations in a family with parkinson ism-Lack of genotype-phenotype correlation. (PubMed id 18644660)^{1, 9} Marras C....Rogaeva E. (2010)
143. Multiple LRRK2 variants modulate risk of Parkinson di sease: a Chinese multicenter study. (PubMed id 20186690)^{1, 9} Tan E.K....Wu R.M. (2010)
144. Parkinson's disease-related LRRK2 G2019S mutation res ults from independent mutational events in humans. (PubMed id 20197411)^{1, 9} Lesage S....Brice A. (2010)
145. Screening for LRRK2 R1441 mutations in a cohort of PS P patients from Germany. (PubMed id 19538213)^{1, 9} Madzar D....Gasser T. (2009)
146. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. (PubMed id 19405094)^{1, 9} Nuytemans K....Theuns J. (2009)
147. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. (PubMed id 19756366)^{1, 9} Thaler A....Giladi N. (2009)
148. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. (PubMed id 19397894)^{1, 9} Reichling L.J. and Riddle S.M. (2009)
149. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. (PubMed id 18804399)^{1, 9} Hasegawa K....Yagishita S. (2009)
150. Lrrk2 interaction with alpha-synuclein in diffuse Lew y body disease. (PubMed id 19878656)^{1, 9} Qing H....McGeer P.L. (2009)
151. Lrrk2 phosphorylates alpha synuclein at serine 129: P arkinson disease implications. (PubMed id 19576176)^{1, 9} Qing H....McGeer P.L. (2009)
152. Leucine-rich repeat kinase 2 expression leads to aggr esome formation that is not associated with alpha-synuclein inclusions. (PubMed id 19535993)^{1, 9} Waxman E.A....Giasson B.I. (2009)
153. The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy. (PubMed id 19513331)^{1, 9} Cho J.W....Jeon B.S. (2009)
154. I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular deg radation rate than the wild-type molecule. (PubMed id 19833102)^{1, 9} Ohta E....Obata F. (2009)
155. Molecular analyses of the LRRK2 gene in European and North-African autosomal dominant Parkinson's disease. (PubMed id 19357115)^{1, 9} Lesage S....Brice A. (2009)
156. Leucine-Rich Repeat Kinase 2 interacts with Parkin, D J-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. (PubMed id 19692353)^{1, 9} Venderova K....Park D.S. (2009)
157. Zeroing in on LRRK2-linked pathogenic mechanisms in P arkinson's disease. (PubMed id 18973807)^{1, 9} Biskup S. and West A.B. (2009)
158. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. (PubMed id 19735093)^{1, 9} MartA--MassA^ J.F....de Munain A.L. (2009)
159. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population. (PubMed id 18716801)^{1, 9} Lu C.S....Bonifati V. (2008)
160. Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. (PubMed id 18098275)^{1, 9} Clarimon J....Kulisevsky J. (2008)
161. Recent advances in the genetics of dementia with lewy bodies. (PubMed id 18541113)^{1, 9} Bonifati V. (2008)
162. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. (PubMed id 18337586)^{1, 9} Haugarvoll K....Wszolek Z.K. (2008)
163. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. (PubMed id 18378882)^{1, 9} Moro E....Klein C. (2008)
164. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. (PubMed id 18201193)^{1, 9} An X.K....Zhang Z.J. (2008)
165. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. (PubMed id 18397888)^{1, 9} Greggio E....Cookson M.R. (2008)
166. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. (PubMed id 18486522)^{1, 9} Mellick G.D....Hattori N. (2008)
167. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. (PubMed id 17230458)^{1, 9} Ozelius L.J....Shults C.W. (2007)
168. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. (PubMed id 17151837)^{1, 9} Dachsel J.C....Farrer M.J. (2007)
169. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. (PubMed id 17385669)^{1, 9} White L.R....Aasly J.O. (2007)
170. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. (PubMed id 17222580)^{1, 9} Farrer M.J....Wu R.M. (2007)
171. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease. (PubMed id 17596714)^{1, 9} Lesage S....Brice A. (2007)
172. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families. (PubMed id 17395370)^{1, 9} Ohta E....Obata F. (2007)
173. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. (PubMed id 17625107)^{1, 9} Goldstein D.S....Hallett M. (2007)
174. Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. (PubMed id 17720280)^{1, 9} Tan E.K....Zhao Y. (2007)
175. No association between the LRRK2 G2019S mutation and Alzheimer's disease in Italy. (PubMed id 17846883)^{1, 9} Tedde A....Sorbi S. (2007)
176. PARK8 LRRK2 parkinsonism. (PubMed id 16822348)^{1, 9} Haugarvoll K. and Wszolek Z.K. (2006)
177. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. (PubMed id 16602113)^{1, 9} Tan E.K....Liu J.J. (2006)
178. Molecular genetic findings in LRRK2 American, Canadian and German families. (PubMed id 17017534)^{1, 9} Gasser T. (2006)
179. LRRK2 mutations are a common cause of Parkinson's disease in Spain. (PubMed id 16643318)^{1, 9} Mata I.F....Alvarez V. (2006)
180. Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. (PubMed id 16632201)^{1, 9} Saunders-Pullman R....Ozelius L.J. (2006)
181. LRRK2 mutations in a clinic-based cohort of Parkinson's disease. (PubMed id 17116211)^{1, 9} Scholz S....Okun M.S. (2006)
182. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia. (PubMed id 17044089)^{1, 9} Pchelina S.N....Schwarzman A.L. (2006)
183. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. (PubMed id 16781064)^{1, 9} Eblan M.J....Sidransky E. (2006)
184. Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. (PubMed id 16671078)^{1, 9} Isaias I.U....Antonini A. (2006)
185. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. (PubMed id 16750929)^{1, 9} Goldwurm S....Pezzoli G. (2006)
186. Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. (PubMed id 16275903)^{1, 9} Li C. and Beal M.F. (2005)
187. [The absence of the common LRRK2 G2019S mutation in 12 0 young onset Hungarian Parkinon's disease patients]. (PubMed id 23074843)¹ Balicza P....Molnar M.J. (2012)
188. LRRK2 Parkinson disease mutations enhance its microtub ule association. (PubMed id 22080837)¹ Kett L.R....Dauer W.T. (2012)
189. Evaluation of the role of LRRK2 gene in Parkinson's di sease in an East Indian cohort. (PubMed id 22684232)¹ Sadhukhan T....Ray J. (2012)
190. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes mo dulated by LRRK2 activity. (PubMed id 21972245)¹ Nikonova E.V....Dawson T.M. (2012)
191. A DNA resequencing array for genes involved in Parkins on's disease. (PubMed id 22243833)¹ Wilkins E.J....Horne M.K. (2012)
192. Comprehensive research synopsis and systematic meta-an alyses in Parkinson's disease genetics: The PDGene database. (PubMed id 22438815)¹ Lill C.M....Bertram L. (2012)
193. LRRK2 phosphorylates tubulin-associated tau but not th e free molecule: LRRK2-mediated regulation of the tau-tubulin association and ne urite outgrowth. (PubMed id 22303461)¹ Kawakami F....Obata F. (2012)
194. Regulation of physiologic actions of LRRK2: focus on a utophagy. (PubMed id 22204929)¹ Ferree A....Wolozin B. (2012)
195. Leucine-rich repeat kinase 2 regulates autophagy through a calcium- dependent pathway involving NAADP. (PubMed id 22012985)² Gomez-Suaga P.... Hilfiker S. (2012)
196. Association between LRRK2 and 4E-BP1 protein levels i n normal and malignant cells. (PubMed id 21922152)¹ Pons B....RamA^n y Cajal S. (2012)
197. AMP kinase activation mitigates dopaminergic dysfuncti on and mitochondrial abnormalities in Drosophila models of Parkinson's disease. (PubMed id 23055502)¹ Ng C.H....Lim K.L. (2012)
198. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Za mbian patients with Parkinson's disease. (PubMed id 22445250)¹ Yonova-Doing E....Bonifati V. (2012)
199. LRRK2 inhibition attenuates microglial inflammatory re sponses. (PubMed id 22302802)¹ Moehle M.S....West A.B. (2012)
200. Progressive degeneration of human neural stem cells ca used by pathogenic LRRK2. (PubMed id 23075850)¹ Liu G.H....Izpisua Belmonte J.C. (2012)
201. Cerebral pathological and compensatory mechanisms in t he premotor phase of leucine-rich repeat kinase 2 parkinsonism. (PubMed id 23250886)¹ van Nuenen B.F....Toni I. (2012)
202. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutatio ns are rare cause of Parkinson's disease in South Indian patients. (PubMed id 22436655)¹ Vishwanathan Padmaja M....Ramesh A. (2012)
203. Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application. (PubMed id 22166428)¹ Yue Z. (2012)
204. GST P1, a novel downstream regulator of LRRK2, G2019S- induced neuronal cell death. (PubMed id 22652643)¹ Chen J....Chen J. (2012)
205. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated pri mary microglial cells and resultant neurotoxicity. (PubMed id 22342962)¹ Gillardon F....Draheim H. (2012)
206. Brain-derived neurotrophic factor (BDNF) genetic polym orphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parki nson's disease. (PubMed id 21924942)¹ Liu J....Chan P. (2012)
207. Phosphorylation of LRRK2 serines 955 and 973 is disrup ted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. (PubMed id 22004453)¹ Doggett E.A....Nichols R.J. (2012)
208. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. (PubMed id 22323743)¹ Inzelberg R....Hassin-Baer S. (2012)
209. GTPase activity and neuronal toxicity of Parkinson's d isease-associated LRRK2 is regulated by ArfGAP1. (PubMed id 22363216)¹ Stafa K....Moore D.J. (2012)
210. Association of Parkinson's disease with six single nuc leotide polymorphisms located in four PARK genes in the northern Han Chinese pop ulation. (PubMed id 22575062)¹ Zhou Y....Pang H. (2012)
211. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756). (PubMed id 22607035)¹ Deng X. and S Gray N. (2012)
212. Genetic analysis of LRRK2 A419V variant in ethnic Chin ese. (PubMed id 22418733)¹ Li N.N....Peng R. (2012)
213. LRRK2 regulates mitochondrial dynamics and function th rough direct interaction with DLP1. (PubMed id 22228096)¹ Wang X....Zhu X. (2012)
214. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. (PubMed id 22899650)¹ Berwick D.C. and Harvey K. (2012)
215. Parkinson's disease and immune system: is the culprit LRRKing in the periphery? (PubMed id 22594666)¹ Greggio E....Bubacco L. (2012)
216. ArfGAP1 is a GTPase activating protein for LRRK2: reci procal regulation of ArfGAP1 by LRRK2. (PubMed id 22423108)¹ Xiong Y....Dawson V.L. (2012)
217. Mechanisms of LRRK2-mediated neurodegeneration. (PubMed id 22441981)¹ Tsika E. and Moore D.J. (2012)
218. Re-examination of the dimerization state of leucine-ri ch repeat kinase 2: predominance of the monomeric form. (PubMed id 22047502)¹ Ito G. and Iwatsubo T. (2012)
219. LRRK2 and human disease: a complicated question or a q uestion of complexes? (PubMed id 22253261)¹ Lewis P.A. and Manzoni C. (2012)
220. Cognitive dysfunction in Tunisian LRRK2 associated Par kinson's disease. (PubMed id 22056842)¹ Ben Sassi S....Hentati F. (2012)
221. Screening LRRK2 gene mutations in patients with Parkin son's disease in Ghana. (PubMed id 21842440)¹ Cilia R....Pezzoli G. (2012)
222. Roco kinase structures give insights into the mechanis m of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. (PubMed id 22689969)¹ Gilsbach B.K....Kortholt A. (2012)
223. [Apoptosis of peripheral blood lymphocytes in patients with LRRK2-assoctated Parkinson's disease]. (PubMed id 22567899)¹ Usenko T.S....Pchelina S.N. (2012)
224. The G2385R variant of leucine-rich repeat kinase 2 ass ociated with Parkinson's disease is a partial loss-of-function mutation. (PubMed id 22612223)¹ Rudenko I.N....Cookson M.R. (2012)
225. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. (PubMed id 22528366)¹ Elliott D.A....Kwok J.B. (2012)
226. Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis. (PubMed id 22575234)¹ Wu X....Qin S.Y. (2012)
227. Age at onset in LRRK2-associated PD is modified by SNC A variants. (PubMed id 22669510)¹ Botta-Orfila T....Tolosa E. (2012)
228. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. (PubMed id 22038903)¹ Lorenzo-Betancor O....Pastor P. (2012)
229. Mutation analysis of LRRK2, SCNA, UCHL1, HtrA2 and GIG YF2 genes in Chinese patients with autosomal dorminant Parkinson's disease. (PubMed id 22503729)¹ Tian J.Y....Tang B.S. (2012)
230. The synaptic function of LRRK2. (PubMed id 22988863)¹ Lee S....Lu B. (2012)
231. Kinase signaling dysfunction in Parkinson's disease: a reverse genetic approach in Drosophila. (PubMed id 22486164)¹ Huang Y....Li C. (2012)
232. Neurodegenerative phenotypes in an A53T a-synuclein tr ansgenic mouse model are independent of LRRK2. (PubMed id 22357653)¹ Daher J.P....Moore D.J. (2012)
233. Leucine-rich repeat kinase 2 disturbs mitochondrial dy namics via Dynamin-like protein. (PubMed id 22639965)¹ Niu J....Xu Z. (2012)
234. LRRK2 controls an EndoA phosphorylation cycle in synap tic endocytosis. (PubMed id 22998870)¹ Matta S....Verstreken P. (2012)
235. A Korean Parkinson's disease family with the LRRK2 p.T yr1699Cys mutation showing clinical heterogeneity. (PubMed id 22162019)¹ Kim J.S....Kim H.T. (2012)
236. Screening for novel LRRK2 inhibitors using a high-thro ughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. (PubMed id 22952710)¹ Hermanson S.B....Bi K. (2012)
237. Olfactory dysfunction in LRRK2 G2019S mutation carrie rs. (PubMed id 21753159)¹ Saunders-Pullman R....Bressman S.B. (2011)
238. Pathogenic LRRK2 mutations do not alter gene expressi on in cell model systems or human brain tissue. (PubMed id 21799870)¹ Devine M.J....Lewis P.A. (2011)
239. Genomewide linkage study of modifiers of LRRK2-relate d Parkinson's disease. (PubMed id 21661047)¹ Latourelle J.C....Foroud T. (2011)
240. Clinical and brain imaging characteristics in leucine- rich repeat kinase 2-associated PD and asymptomatic mutation carriers. (PubMed id 21989859)¹ Brockmann K....Gasser T. (2011)
241. Kin-cohort analysis of LRRK2-G2019S penetrance in Par kinson's disease. (PubMed id 21714003)¹ Goldwurm S....Pezzoli G. (2011)
242. LRRK2 controls synaptic vesicle storage and mobilizat ion within the recycling pool. (PubMed id 21307259)¹ Piccoli G....Ueffing M. (2011)
243. Do interactions between SNCA, MAPT, and LRRK2 genes co ntribute to Parkinson's disease susceptibility? (PubMed id 21816655)¹ Biernacka J.M....Maraganore D.M. (2011)
244. Dopaminergic neuronal loss, reduced neurite complexit y and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK 2. (PubMed id 21494637)¹ Ramonet D....Moore D.J. (2011)
245. Chromosomal amplification of leucine-rich repeat kina se-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thy roid carcinomas. (PubMed id 21220347)¹ Looyenga B.D....MacKeigan J.P. (2011)
246. Transcriptional profile of Parkinson blood mononuclea r cells with LRRK2 mutation. (PubMed id 20096956)¹ Mutez E....Chartier-Harlin M.C. (2011)
247. Comprehensive mutational analysis of LRRK2 reveals var iants supporting association with autosomal dominant Parkinson's disease. (PubMed id 21796139)¹ Seki N....Tsuji S. (2011)
248. LRRK2 R1398H polymorphism is associated with decrease d risk of Parkinson's disease in a Han Chinese population. (PubMed id 21159540)¹ Chen L....Zeng J. (2011)
249. Role of LRRK2 kinase dysfunction in Parkinson disease . (PubMed id 21676337)¹ Kumar A. and Cookson M.R. (2011)
250. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). (PubMed id 21954089)¹ Sierra M....Infante J. (2011)
251. LRRK2 G2019S mutation does not contribute to Parkinso n's disease in South India. (PubMed id 21483109)¹ Vijayan B....Kishore A. (2011)
252. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. (PubMed id 21312285)¹ BrA1ggemann N....Saunders-Pullman R. (2011)
253. LRRK2 Pro755Leu variant in ethnic Chinese population with Parkinson's disease. (PubMed id 21406209)¹ Yao L.Y....Shen L. (2011)
254. LRRK2 directly phosphorylates Akt1 as a possible phys iological substrate: impairment of the kinase activity by Parkinson's disease-a ssociated mutations. (PubMed id 21658387)¹ Ohta E....Obata F. (2011)
255. Association of LRRK2 exonic variants with susceptibil ity to Parkinson's disease: a case-control study. (PubMed id 21885347)¹ Ross O.A....Farrer M.J. (2011)
256. LRRK2 kinase activity is dependent on LRRK2 GTP bindi ng capacity but independent of LRRK2 GTP binding. (PubMed id 21858031)¹ Taymans J.M....Cookson M.R. (2011)
257. The LRRK2 R1441C mutation is more frequent than G2019 S in Parkinson's disease patients from southern Italy. (PubMed id 21538529)¹ Criscuolo C....De Michele G. (2011)
258. Phenotype in parkinsonian and nonparkinsonian LRRK2 G 2019S mutation carriers. (PubMed id 21753163)¹ Marras C....Lang A.E. (2011)
259. Web-based genome-wide association study identifies tw o novel loci and a substantial genetic component for Parkinson's disease. (PubMed id 21738487)¹ Do C.B....Eriksson N. (2011)
260. a-Synuclein, leucine-rich repeat kinase-2, and mangane se in the pathogenesis of Parkinson disease. (PubMed id 21238487)¹ Covy J.P. and Giasson B.I. (2011)
261. Subclinical signs in LRRK2 mutation carriers. (PubMed id 21641848)¹ Johansen K.K....Aasly J.O. (2011)
262. Temporal expression of mutant LRRK2 in adult rats imp airs dopamine reuptake. (PubMed id 21698001)¹ Zhou H....Xia X.G. (2011)
263. LRRK2 mutant iPSC-derived DA neurons demonstrate incr eased susceptibility to oxidative stress. (PubMed id 21362567)¹ Nguyen H.N....Pera R.R. (2011)
264. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. (PubMed id 21168496)¹ Winner B....Gage F.H. (2011)
265. Lrrk2 S1647T and BDNF V66M interact with environmenta l factors to increase risk of Parkinson's disease. (PubMed id 21167764)¹ Lin C.H....Hu F.C. (2011)
266. LRRK2 Parkinson's disease: from animal models to cell ular mechanisms. (PubMed id 21679126)¹ Lin C.H....Chien C.T. (2011)
267. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. (PubMed id 21961647)¹ Liu M....Glicksman M.A. (2011)
268. Gait alterations in healthy carriers of the LRRK2 G20 19S mutation. (PubMed id 21280089)¹ Mirelman A....Hausdorff J.M. (2011)
269. Rac1 protein rescues neurite retraction caused by G20 19S leucine-rich repeat kinase 2 (LRRK2). (PubMed id 21454543)¹ Chan D....Wolozin B. (2011)
270. Olfactory deficits and cardiac 123I-MIBG in Parkinson 's disease related to the LRRK2 R1441G and G2019S mutations. (PubMed id 21611983)¹ Ruiz-MartA-nez J....MartA- MassA^ J.F. (2011)
271. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. (PubMed id 21248752)² Varela I....Futreal P.A. (2011)
272. 123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. (PubMed id 21221623)¹ Valldeoriola F....Tolosa E. (2011)
273. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. (PubMed id 21738687)¹ ThAcvenet J....Sagot Y.J. (2011)
274. Mood and cognition in leucine-rich repeat kinase 2 G20 19S Parkinson's disease. (PubMed id 21611978)¹ Shanker V....Bressman S. (2011)
275. LRRK2 expression in idiopathic and G2019S positive Par kinson's disease subjects: a morphological and quantitative study. (PubMed id 21696411)¹ Sharma S....Holton J.L. (2011)
276. A study of six point mutation analysis of LRRK2 gene in Chinese mainland patients with Parkinson's disease. (PubMed id 21234781)¹ Hu Z.X....Zhang B.R. (2011)
277. Death-associated protein kinase 1 variation and Parkin son's disease. (PubMed id 21749573)¹ Dachsel J.C....Ross O.A. (2011)
278. A QUICK screen for Lrrk2 interaction partners--leucine -rich repeat kinase 2 is involved in actin cytoskeleton dynamics. (PubMed id 20876399)¹ Meixner A....Ueffing M. (2011)
279. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide associat ion studies. (PubMed id 21292315)¹  ....Wood N.W. (2011)
280. Dysregulated LRRK2 signaling in response to endoplasm ic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. (PubMed id 21857923)¹ Yuan Y....Feng Z. (2011)
281. Insight into the mode of action of the LRRK2 Y1699C p athogenic mutant. (PubMed id 21073465)¹ DaniAls V....Taymans J.M. (2011)
282. Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. (PubMed id 21632271)¹ Mata I.F....Ross O.A. (2011)
283. The lrrk2 p.Gly2019Ser mutation is uncommon in a Dani sh cohort with various neurodegenerative disorders. (PubMed id 21353620)¹ Bech S....Hjermind L.E. (2011)
284. G2019S mutation of the leucine-rich repeat kinase 2 ge ne in a cohort of Egyptian patients with Parkinson's disease. (PubMed id 21699405)¹ Hashad D.I....Saad M.A. (2011)
285. [Clinical features of LRRK2-associated Parkinson's dis ease]. (PubMed id 22433811)¹ Pchelina S.N....Iakimovskii A.F. (2011)
286. LRRK2 G2019S mutations may be increased in Puerto Ric ans. (PubMed id 21449009)¹ Saunders-Pullman R....Bressman S.B. (2011)
287. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellula r functions. (PubMed id 22077787)¹ Drolet R.E....Kern J.T. (2011)
288. Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? (PubMed id 20969957)¹ Plowey E.D. and Chu C.T. (2011)
289. I+-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. (PubMed id 21720016)¹ Kondo K....Teshima R. (2011)
290. Frequencies of LRRK2 variants in Thai patients with P arkinson's disease: evidence for an R1628P founder. (PubMed id 20571044)¹ Pulkes T....Tiamkao S. (2011)
291. Parkinson's disease-linked LRRK2 is expressed in circ ulating and tissue immune cells and upregulated following recognition of microb ial structures. (PubMed id 21552986)¹ Hakimi M....Schlossmacher M.G. (2011)
292. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. (PubMed id 21806997)¹ Webber P.J....West A.B. (2011)
293. ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchang e factor for leucine-rich repeat kinase 2. (PubMed id 21048939)¹ Haebig K....Bonin M. (2010)
294. The G2019S pathogenic mutation disrupts sensitivity o f leucine-rich repeat kinase 2 to manganese kinase inhibition. (PubMed id 20626563)¹ Covy J.P. and Giasson B.I. (2010)
295. Worldwide frequency of G2019S LRRK2 mutation in Parki nson's disease: a systematic review. (PubMed id 19945904)¹ Correia Guedes L....Sampaio C. (2010)
296. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disea se associated protein kinase LRRK2. (PubMed id 20108944)¹ Gloeckner C.J....Ueffing M. (2010)
297. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. (PubMed id 21060682)¹ Pungaliya P.P....Braithwaite S.P. (2010)
298. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. (PubMed id 20379614)¹ Rose J.E....Uhl G.R. (2010)
299. LRRK2 G2019S in the North African population: a revie w. (PubMed id 20413974)¹ Benamer H.T. and de Silva R. (2010)
300. The LRRK2 G2385R variant is a risk factor for sporadi c Parkinson's disease in the Korean population. (PubMed id 19854095)¹ Kim J.M....Jeon B.S. (2010)
301. Dopamine turnover increases in asymptomatic LRRK2 mut ations carriers. (PubMed id 20939082)¹ Sossi V....Stoessl J.A. (2010)
302. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update . (PubMed id 20506312)¹ Nuytemans K....Van Broeckhoven C. (2010)
303. LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: a case-control study in Japan. (PubMed id 20673920)¹ Miyake Y....Nagai M. (2010)
304. LRRK2-mediated neurodegeneration and dysfunction of d opaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. (PubMed id 20382224)¹ Yao C....Chen S.G. (2010)
305. Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson's disease in Southern China. (PubMed id 20629711)¹ Zheng Y....Chen L. (2010)
306. The role of leucine-rich repeat kinase 2 (LRRK2) in P arkinson's disease. (PubMed id 21088684)¹ Cookson M.R. (2010)
307. Novel pathogenic LRRK2 p.Asn1437His substitution in f amilial Parkinson's disease. (PubMed id 20669305)¹ Aasly J.O....Farrer M.J. (2010)
308. Structural imaging in the presymptomatic stage of gen etically determined parkinsonism. (PubMed id 20483373)¹ Reetz K....Binkofski F. (2010)
309. LRRK2 G2019S mutation in Parkinson's disease: a neuro psychological and neuropsychiatric study in a large Algerian cohort. (PubMed id 20933457)¹ Belarbi S....Tazir M. (2010)
310. Absence of commonly reported leucine-rich repeat kina se 2 mutations in eastern Indian Parkinson's disease patients. (PubMed id 20722494)¹ Sanyal J....Rao V.R. (2010)
311. Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis. (PubMed id 21072187)¹ Laukens D....De Vos M. (2010)
312. Inhibitors of leucine-rich repeat kinase-2 protect ag ainst models of Parkinson's disease. (PubMed id 20729864)¹ Lee B.D....Dawson T.M. (2010)
313. LRRK2 G2019S mutation induces dendrite degeneration t hrough mislocalization and phosphorylation of tau by recruiting autoactivated G SK3A9. (PubMed id 20881132)¹ Lin C.H....Chien C.T. (2010)
314. LRRK2 variation and Parkinson's disease in African Am ericans. (PubMed id 20669299)¹ Ross O.A....Wszolek Z.K. (2010)
315. Involvement of the cerebral cortex in Parkinson disea se linked with G2019S LRRK2 mutation without cognitive impairment. (PubMed id 20232069)¹ Gomez A. and Ferrer I. (2010)
316. Detailed haplotype-tagging study of germline variatio n of MUC19 in inflammatory bowel disease. (PubMed id 19714762)¹ Phillips A.M....Satsangi J. (2010)
317. Membrane localization of LRRK2 is associated with inc reased formation of the highly active LRRK2 dimer and changes in its phosphoryl ation. (PubMed id 20515039)¹ Berger Z....Lavoie M.J. (2010)
318. LRRK2 is involved in the IFN-gamma response and host response to pathogens. (PubMed id 20921534)¹ Gardet A....Podolsky D.K. (2010)
319. A novel LRRK2 mutation in a mainland Chinese patient with familial Parkinson's disease. (PubMed id 19879329)¹ Wang L....Tang B.S. (2010)
320. Association between GBA L444P mutation and sporadic P arkinson's disease from Mainland China. (PubMed id 20004703)¹ Mao X.Y....Peng R. (2010)
321. A comparative study of Lrrk2 function in primary neur onal cultures. (PubMed id 20850369)¹ DAochsel J.C....Farrer M.J. (2010)
322. 14-3-3 binding to LRRK2 is disrupted by multiple Parki nson's disease-associated mutations and regulates cytoplasmic localization. (PubMed id 20642453)¹ Nichols R.J....Alessi D.R. (2010)
323. Leucine-rich repeat kinase 2 is associated with the e ndoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lew y bodies in Parkinson disease. (PubMed id 20720502)¹ Vitte J....Brice A. (2010)
324. Mitochondrial impairment in patients with Parkinson d isease with the G2019S mutation in LRRK2. (PubMed id 21115957)¹ Mortiboys H....Bandmann O. (2010)
325. Self-report of cognitive impairment and mini-mental s tate examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. (PubMed id 20182943)¹ Alcalay R.N....Caccappolo E. (2010)
326. Genetic analysis of LRRK2 functional domains in Brazi lian patients with Parkinson's disease. (PubMed id 20443975)¹ Abdalla-Carvalho C.B....Pimentel M.M. (2010)
327. Reevaluation of phosphorylation sites in the Parkinso n disease-associated leucine-rich repeat kinase 2. (PubMed id 20595391)¹ Li X....Dawson V.L. (2010)
328. Low frequency of common LRRK2 mutations in Mexican pa tients with Parkinson's disease. (PubMed id 20727385)¹ Yescas P....Alonso M.E. (2010)
329. LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. (PubMed id 20173330)¹ Hsu C.H....Wolozin B. (2010)
330. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. (PubMed id 21102463)¹ Franke A....Parkes M. (2010)
331. LRRK2 G2019S mutation: frequency and haplotype data i n South African Parkinson's disease patients. (PubMed id 20544233)¹ Bardien S....Carr J. (2010)
332. Comprehensive sequencing of the LRRK2 gene in patient s with familial Parkinson's disease from North Africa. (PubMed id 20721913)¹ Jasinska-Myga B....Farrer M.J. (2010)
333. Analysis of GWAS-linked loci in Parkinson disease rea ffirms PARK16 as a susceptibility locus. (PubMed id 20697102)¹ Tan E.K....Liu J.J. (2010)
334. Penetrance in Parkinson's disease related to the LRRK 2 R1441G mutation in the Basque country (Spain). (PubMed id 20721916)¹ Ruiz-MartA-nez J....MassA^ J.F. (2010)
335. LRRK2 kinase regulates synaptic morphology through dis tinct substrates at the presynaptic and postsynaptic compartments of the Drosoph ila neuromuscular junction. (PubMed id 21159966)¹ Lee S....Lu B. (2010)
336. Pathogenic LRRK2 negatively regulates microRNA-mediat ed translational repression. (PubMed id 20671708)¹ Gehrke S....Lu B. (2010)
337. [Genetic screening for the LRRK2, G2019S and R1441 co don mutations in Parkinson's disease patients from Extremadura, Spain] (PubMed id 20473834)¹ MorA!n J.M....Fuentes J.M. (2010)
338. Common genetic variation in the HLA region is associa ted with late-onset sporadic Parkinson's disease. (PubMed id 20711177)¹ Hamza T.H....Payami H. (2010)
339. LRRK2 G2019S mutations are associated with an increas ed cancer risk in Parkinson disease. (PubMed id 20818610)¹ Saunders-Pullman R....Bressman S.B. (2010)
340. Prevention of intracellular degradation of I2020T mut ant LRRK2 restores its protectivity against apoptosis. (PubMed id 19912990)¹ Ohta E....Obata F. (2010)
341. Olfactory heterogeneity in LRRK2 related Parkinsonism . (PubMed id 20818658)¹ Silveira-Moriyama L....Lees A.J. (2010)
342. Impaired dopaminergic neurotransmission and microtubu le-associated protein tau alterations in human LRRK2 transgenic mice. (PubMed id 20659558)¹ Melrose H.L....Farrer M.J. (2010)
343. Analysis of 39 Crohn's disease risk loci in Swedish i nflammatory bowel disease patients. (PubMed id 19760754)¹ TAPrkvist L....Pettersson S. (2010)
344. LRRK2 and GBA mutations differentially affect the ini tial presentation of Parkinson disease. (PubMed id 19458969)¹ Gan-Or Z....Orr-Urtreger A. (2010)
345. Analysis of the LRRK2 Gly2385Arg variant in Alzheimer 's disease in Taiwan. (PubMed id 19640773)¹ Chang T.Y....Huang C.C. (2010)
346. Clinical expression of LRRK2 G2019S mutations in the elderly. (PubMed id 20721910)¹ San Luciano M....Saunders-Pullman R. (2010)
347. Haplotype analysis of Lrrk2 R1441H carriers with park insonism. (PubMed id 18952485)¹ Ross O.A....Farrer M.J. (2009)
348. Genomewide association study of leprosy. (PubMed id 20018961)¹ Zhang F.R....Liu J.J. (2009)
349. No TARDBP mutations in a French Canadian population of patients with Parkinson disease. (PubMed id 19204172)¹ Kabashi E....Rouleau G.A. (2009)
350. LRRK2 R1628P contributes to Parkinson's disease susce ptibility in Chinese Han populations from mainland China. (PubMed id 19699188)¹ Yu L....Xu Y. (2009)
351. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. (PubMed id 19412725)¹ Hassin-Baer S....Friedman E. (2009)
352. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. (PubMed id 19308469)¹ Mata I.F....Zabetian C.P. (2009)
353. Regulation of LRRK2 stability by the E3 ubiquitin lig ase CHIP. (PubMed id 19536328)¹ Ding X. and Goldberg M.S. (2009)
354. Common mutations in the LRRK2 exon 41 are not responsible for essential tremor in Italian patients. (PubMed id 18556235)¹ Vitale C....Mandich P. (2009)
355. Motor phenotype of LRRK2 G2019S carriers in early-ons et Parkinson disease. (PubMed id 20008657)¹ Alcalay R.N....Marder K.S. (2009)
356. Metabolomic profiling in LRRK2-related Parkinson's di sease. (PubMed id 19847307)¹ Johansen K.K....Bogdanov M. (2009)
357. Identification of four novel potentially Parkinson's disease associated LRRK2 variations among Iranian patients. (PubMed id 19800393)¹ Shojaee S....Elahi E. (2009)
358. Parkinson's disease and low frequency alleles found t ogether throughout LRRK2. (PubMed id 19489756)¹ PaisA!n-Ruiz C....Corder E.H. (2009)
359. A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients. (PubMed id 19353692)¹ Shojaee S....Elahi E. (2009)
360. Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? (PubMed id 19224617)¹ Sutherland G.T....Mellick G.D. (2009)
361. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. (PubMed id 19196961)¹ Ko H.S....Dawson V.L. (2009)
362. Genome-wide association study identifies common varia nts at four loci as genetic risk factors for Parkinson's disease. (PubMed id 19915576)¹ Satake W....Toda T. (2009)
363. Genome-wide association study reveals genetic risk un derlying Parkinson's disease. (PubMed id 19915575)¹ SimA^n-SA!nchez J....Gasser T. (2009)
364. Mutations in the LRRK2 Roc-COR tandem domain link Par kinson's disease to Wnt signalling pathways. (PubMed id 19625296)¹ Sancho R.M....Harvey K. (2009)
365. LRRK2 gene variation and its contribution to Parkinso n disease. (PubMed id 19472409)¹ PaisA!n-Ruiz C. (2009)
366. A clinical, neuropsychological and olfactory evaluati on of a large family with LRRK2 mutations. (PubMed id 18718805)¹ Lohmann E....Brice A. (2009)
367. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model . (PubMed id 19640926)¹ Alegre-Abarrategui J....Wade-Martins R. (2009)
368. LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. (PubMed id 19672984)¹ Zhang Z....Peng R. (2009)
369. A LRRK2 G2019S mutation carrier from Turkey shares th e Japanese haplotype. (PubMed id 19172321)¹ Pirkevi C....BaA9ak A.N. (2009)
370. Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson's disease and mutations in PARK2 or PARK8 genes. (PubMed id 19330201)¹ Barsottini O.G....Andrade L.A. (2009)
371. Interaction of elongation factor 1-alpha with leucine -rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro . (PubMed id 19559761)¹ Gillardon F. (2009)
372. The small GTPase activity of the ROC domain from LRRK 2, a Parkinson's disease related protein. (PubMed id 20001906)¹ Fu Q.S....Hu H.Y. (2009)
373. Phosphorylation of ezrin/radixin/moesin proteins by L RRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis . (PubMed id 19890007)¹ Parisiadou L....Cai H. (2009)
374. Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuri es. (PubMed id 19283415)¹ Bar-Shira A....Orr-Urtreger A. (2009)
375. The Parkinson's disease kinase LRRK2 autophosphorylat es its GTPase domain at multiple sites. (PubMed id 19733152)¹ Greggio E....Cookson M.R. (2009)
376. Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. (PubMed id 19006185)¹ Covy J.P....Giasson B.I. (2009)
377. Parkinson disease, LRRK2 and the endocytic-autophagic pathway. (PubMed id 19770575)¹ Alegre-Abarrategui J. and Wade-Martins R. (2009)
378. LRRK2 variant associated with Alzheimer's disease. (PubMed id 20018409)¹ Zhao Y....Tan E.K. (2009)
379. ROCO kinase activity is controlled by internal GTPase function. (PubMed id 18544747)¹ Weiss B. (2008)
380. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. (PubMed id 18539535)¹ Hulihan M.M....Farrer M.J. (2008)
381. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. (PubMed id 18539534)¹ Healy D.G....Wood N.W. (2008)
382. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. (PubMed id 19029519)¹ Nandhagopal R....Stoessl A.J. (2008)
383. Analysis of the LRRK2 Gly2385Arg variant in primary dystonia and multiple system atrophy in Taiwan. (PubMed id 18450497)¹ Lu C.S....Wu-Chou Y.H. (2008)
384. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. (PubMed id 18809839)¹ Silveira-Moriyama L....Lees A.J. (2008)
385. Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. (PubMed id 18211709)¹ Bras J....Singleton A. (2008)
386. Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. (PubMed id 18665323)¹ Djaldetti R....Melamed E. (2008)
387. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. (PubMed id 18781329)¹ Tan E.K....Zhao Y. (2008)
388. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. (PubMed id 18412265)¹ Ross O.A....Wu R.M. (2008)
389. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. (PubMed id 18587394)¹ Barrett J.C....Daly M.J. (2008)
390. Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. (PubMed id 18666856)¹ Change N....Lucotte G. (2008)
391. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. (PubMed id 17999435)¹ Munhoz R.P....Rogaeva E. (2008)
392. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease. (PubMed id 18484993)¹ Moller J.C....Oertel W.H. (2008)
393. Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? (PubMed id 18981379)¹ Lesage S....Brice A. (2008)
394. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. (PubMed id 18353371)¹ Gaig C....Tolosa E. (2008)
395. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. (PubMed id 18182054)¹ Plowey E.D....Chu C.T. (2008)
396. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. (PubMed id 18927607)¹ Okubadejo N....Bras J. (2008)
397. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. (PubMed id 18464276)¹ de Carvalho Aguiar P....Andrade L.A. (2008)
398. Investigating convergent actions of genes linked to familial Parkinson's disease. (PubMed id 18322385)¹ Wolozin B....Riley M. (2008)
399. Essential tremor and the common LRRK2 G2385R variant. (PubMed id 18316234)¹ Tan E.K....Zhao Y. (2008)
400. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. (PubMed id 18634852)¹ Han B.S....Kim K.S. (2008)
401. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. (PubMed id 19020907)¹ Gorostidi A....Marti Masso J.F. (2008)
402. LRRK2 P755L variant in sporadic Parkinson's disease. (PubMed id 18923807)¹ Tomiyama H....Hattori N. (2008)
403. Screening of LRRK2 interactants by yeast 2-hybrid analysis. (PubMed id 19001729)¹ Zheng X.Y....Zhang Z.H. (2008)
404. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. (PubMed id 18986508)¹ Latourelle J.C....Myers R.H. (2008)
405. LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients. (PubMed id 18523722)¹ Chan D.K....Wong L. (2008)
406. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. (PubMed id 18230735)¹ Deng J....Cookson M.R. (2008)
407. [Advance of the study on LRRK2 gene in Parkinson's disease] (PubMed id 19065525)¹ Zhang Y. and Chen S. (2008)
408. LRRK2 mutations in Basque patients with Parkinson's disease. (PubMed id 18848304)¹ Zarranz J.J. and Gomez-Esteban J.C. (2008)
409. Pathogenicity of LRRK2 P755L variant in Parkinson's d isease. (PubMed id 18265005)¹ Tan E.K....Zhao Y. (2008)
410. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. (PubMed id 17880562)¹ Kalinderi K....Kotsis A. (2007)
411. Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease. (PubMed id 17335904)¹ Ghione I....Rango M. (2007)
412. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. (PubMed id 17215492)¹ Goldwurm S....Pezzoli G. (2007)
413. Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. (PubMed id 17225181)¹ Taylor J.P....Farrer M.J. (2007)
414. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. (PubMed id 17149721)¹ Nichols W.C....Foroud T. (2007)
415. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. (PubMed id 17115391)¹ Ishihara L....Hentati F. (2007)
416. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. (PubMed id 17622782)¹ Johnson J....Singleton A.B. (2007)
417. The full-ORF clone resource of the German cDNA consortium. (PubMed id 17974005)² Bechtel S.... Schupp I. (2007)
418. Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis. (PubMed id 16865326)¹ Whittle A.J....Przedborski S. (2007)
419. Common variants in Parkinson's disease. (PubMed id 17377919)¹ Ross O.A....Wu R.M. (2007)
420. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. (PubMed id 17314670)¹ Funayama M....Hattori N. (2007)
421. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? (PubMed id 17938369)¹ Orr-Urtreger A....Giladi N. (2007)
422. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. (PubMed id 17540608)¹ Gonzalez-Fernandez M.C....de Pancorbo M.M. (2007)
423. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease. (PubMed id 17235449)¹ Squillaro T....Ariani F. (2007)
424. The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease. (PubMed id 17352347)¹ Cho J.W....Jeon B.S. (2007)
425. LRRK2 G2019S founder haplotype in the Chinese population. (PubMed id 17083102)¹ Tan E.K....Liu J.J. (2007)
426. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. (PubMed id 17482357)¹ Deng H....Jankovic J. (2007)
427. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. (PubMed id 17960808)¹ Li C....Sheng Di C. (2007)
428. Patterns of somatic mutation in human cancer genomes. (PubMed id 17344846)² Greenman C.... Stratton M.R. (2007)
429. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. (PubMed id 17639429)¹ Miklossy J....McGeer P.L. (2007)
430. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. (PubMed id 17447891)¹ Jaleel M....Alessi D.R. (2007)
431. Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. (PubMed id 17659642)¹ Tan E.K....Liu J.J. (2007)
432. Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. (PubMed id 17324517)¹ Haugarvoll K....Farrer M.J. (2007)
433. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. (PubMed id 17442267)¹ Lewis P.A....Cookson M.R. (2007)
434. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. (PubMed id 17216639)¹ Toft M....Farrer M.J. (2007)
435. The role of common genetic risk variants in Parkinson disease. (PubMed id 17868389)¹ Tan E.K. (2007)
436. LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson's disease. (PubMed id 17470139)¹ Civitelli D....Quattrone A. (2007)
437. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. (PubMed id 16939701)¹ Deng H....Jankovic J. (2006)
438. The importance of LRRK2 mutations in Parkinson disease. (PubMed id 16966498)¹ Schapira A.H. (2006)
439. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. (PubMed id 17017533)¹ Whaley N.R....Wszolek Z.K. (2006)
440. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. (PubMed id 16436782)¹ Ozelius L.J....Bressman S.B. (2006)
441. A novel P755L mutation in LRRK2 gene associated with Parkinson's disease. (PubMed id 17179858)¹ Wu T....Deng X. (2006)
442. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. (PubMed id 16633828)¹ Di Fonzo A....Bonifati V. (2006)
443. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease. (PubMed id 16511860)¹ Fung H.C....Wu Y.R. (2006)
444. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. (PubMed id 17187665)¹ Fung H.C....Wu Y.R. (2006)
445. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. (PubMed id 16622859)¹ Marongiu R....Garavaglia B. (2006)
446. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. (PubMed id 16728648)¹ Zabetian C.P....Kawakami H. (2006)
447. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. (PubMed id 16614029)¹ Williams-Gray C.H....Barker R.A. (2006)
448. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. (PubMed id 16436781)¹ Lesage S....Brice A. (2006)
449. Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. (PubMed id 17160203)¹ Tan E.K. (2006)
450. The finished DNA sequence of human chromosome 12. (PubMed id 16541075)² Scherer S.E.... Gibbs R.A. (2006)
451. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. (PubMed id 17078063)¹ Pankratz N....Nichols W.C. (2006)
452. Lrrk2 and Lewy body disease. (PubMed id 16437559)¹ Ross O.A....Dickson D.W. (2006)
453. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. (PubMed id 16622854)¹ Tomiyama H....Hattori N. (2006)
454. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. (PubMed id 17060595)¹ Spanaki C....Plaitakis A. (2006)
455. Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. (PubMed id 17020475)¹ Kay D.M....Payami H. (2006)
456. Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. (PubMed id 17082220)¹ Nakamura N.... Ochi T. (2006)
457. The pleomorphic pathology of inherited Parkinson's disease: lessons from LRRK2. (PubMed id 16928343)¹ Bonifati V. (2006)
458. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. (PubMed id 15955578)¹ Singleton A.B. (2005)
459. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. (PubMed id 16149095)¹ Bras J.M....Singleton A. (2005)
460. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. (PubMed id 16145815)¹ Lesage S....Brice A. (2005)
461. Genetic testing in Parkinson's disease. (PubMed id 15884041)¹ McInerney-Leo A. (2005)
462. Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. (PubMed id 15146197)¹ Brandenberger R.... Stanton L.W. (2004)
463. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. (PubMed id 14691730)¹ Zimprich A....Gasser T. (2004)
464. Complete sequencing and characterization of 21,243 full-length human cDNAs. (PubMed id 14702039)¹ Ota T.... Sugano S. (2004)
465. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. (PubMed id 11891824)¹ Funayama M....Obata F. (2002)
466. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. (PubMed id 12477932)¹ Strausberg R.L....Marra M.A. (2002)
467. Identifying novel transcripts and novel genes in the human genome by using novel SAGE tags. (PubMed id 12213963)¹ Chen J....Wang S.M. (2002)
468. LRRK2-Related Parkinson Disease (PubMed id 20301387)¹ Farrer M. and Ross O.A. (1993)
469. Parkinson Disease O verview (PubMed id 20301402)¹ Pankratz N.D....Foroud T. (1993)
470. (PubMed id 15987882)⁴ 
471. (PubMed id 15972842)⁴ 
472. [Clinical molecular genetics for PARK8 (LRRK2)] (PubMed id 17713120)⁹ Tomiyama H....Hattori N. (2007)
473. LRRK2 in Parkinson's disease and dementia with Lewy bodies. (PubMed id 17137507)⁹ Zhu X....Chen S.G. (2006)
474. Substrate specificity and inhibitors of LRRK2, a prot ein kinase mutated in Parkinson's disease. (PubMed id 19740074)⁹ Nichols R.J....Alessi D.R. (2009)
475. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. (PubMed id 17120249)⁹ Biskup S....Dawson V.L. (2006)
476. LRRK2 and neurodegeneration. (PubMed id 19142648)⁹ Santpere G. and Ferrer I. (2009)
477. New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2. (PubMed id 19839940)⁹ Liou G.Y. and Gallo K.A. (2009)
478. Clinical features of LRRK2 parkinsonism. (PubMed id 20082991)⁹ Haugarvoll K. and Wszolek Z.K. (2009)
479. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. (PubMed id 19027715)⁹ Covy J.P. and Giasson B.I. (2009)
480. Emerging role of LRRK2 in human neural progenitor cel l cycle progression, survival and differentiation. (PubMed id 19523245)⁹ Milosevic J....Schwarz J. (2009)
481. LRRK2 in Parkinson's disease: function in cells and n eurodegeneration. (PubMed id 19804415)⁹ Webber P.J. and West A.B. (2009)
482. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. (PubMed id 17614947)⁹ Hurley M.J....Jenner P. (2007)
483. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. (PubMed id 16600664)⁹ Guo L....Chen S.G. (2006)
484. LRRK2 expression in normal and pathologic human brain and in human cell lines. (PubMed id 17021400)⁹ Miklossy J....McGeer P.L. (2006)
485. Mechanisms in dominant parkinsonism: The toxic triang le of LRRK2, alpha-synuclein, and tau. (PubMed id 20127702)⁹ Taymans J.M. and Cookson M.R. (2010)
486. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation. (PubMed id 19072560)⁹ Santos-RebouAsas C.B....Pimentel M.M. (2008)
487. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. (PubMed id 17114044)⁹ MacLeod D....Abeliovich A. (2006)
488. LRRK2 in Parkinson's disease: biochemical functions. (PubMed id 19804416)⁹ Anand V.S. and Braithwaite S.P. (2009)
489. A Drosophila model for LRRK2-linked parkinsonism. (PubMed id 18258746)⁹ Liu Z....Smith W.W. (2008)
490. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. (PubMed id 17582365)⁹ Klein C....Lang A.E. (2007)
491. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? (PubMed id 16406842)⁹ Taylor J.P....Farrer M.J. (2006)

External Searches for LRRK2 gene

Genome Databases showing LRRK2 gene

Other Databases showing LRRK2 gene

Specialized Databases showing LRRK2 gene

Products
for LRRK2 gene